Paget's
Disease Can Be Successfully Treated with Breast-Conserving
Therapy
According to results presented at the 2003 San Antonio Breast
Cancer Symposium, Paget's disease confined to the nipple
or areola can be successfully treated with breast-conserving
therapy followed by radiation.
Paget's disease of the breast accounts for only 1% to 4%
of all breast cancers. Paget's disease of the breast often
has symptoms including redness, scaling of the skin, itching,
or burning in the area of the nipple or areola (darker-colored
skin directly surrounding the nipple). The nipple may also
change appearance, including a flattening against the breast,
or a bloody discharge may occur. Approximately half of patients
with Paget's disease of the breast also have a cancerous lump
in the breast that can be felt. Historically, standard treatment
for Paget's disease of the breast included a mastectomy, which
is the surgical removal of the entire breast. However, researchers
have increasingly been using breast-conserving therapy, in
which only a portion of the breast is surgically removed,
for the treatment of Paget's disease that does not appear
to have spread from the area of the nipple instead of mastectomy.
Medical literature on results from breast-conserving therapy
in the treatment of these patients is scarce, and researchers
are beginning to collect more information involving this issue
so that physicians and patients can make the most appropriate
treatment decisions based on sound data.
Researchers from the MD Anderson Cancer Center recently evaluated
data comparing outcomes of patients with Paget's disease of
the breast who were treated with mastectomy or breast-conserving
therapy. This data included 109 patients who were diagnosed
between 1949 and 1993 and the average follow-up was approximately
7 years. For patients who had no cancer outside the area of
the nipple or areola found on scans or no lumps that could
be felt, overall survival, cancer-free survival, and cancer
recurrences occurring at or near the site of origin were equal
between patients treated with mastectomy or breast-conserving
therapy. Patients with more advanced breast cancer, such as
those with cancer spread to lymph nodes, and those younger
than 60 years of age, had worse overall survival than the
rest of the group of patients, regardless of therapy. These
findings are consistent with other types of breast cancer.
The researchers concluded that breast-conserving therapy provides
equal outcomes to mastectomy in patients with Paget's disease
of the breast that is confined to the nipple or areola. 1
Results from a second clinical study evaluating breast-conserving
therapy in Paget's disease of the breast were also presented
at the meeting. Researchers from New York analyzed data involving
45 patients diagnosed between 1990 and 1997 with Paget's disease
that had not spread and were treated with either a mastectomy
or breast-conserving therapy. Approximately half of the patients
underwent a mastectomy and half underwent breast-conserving
therapy. The average time of follow-up was approximately 7
years. Overall survival, recurrence rates and time to recurrence
were all similar between mastectomy and breast-conserving
therapy patients. Cancer recurrences occurred in 17% of patients
treated with breast-conserving therapy, and 14% of patients
treated with a mastectomy. The average time to a cancer recurrence
was approximately 2 years in both groups of patients. Overall
survival was 85% for patients treated with breast-conserving
therapy, and 78% for those treated with a mastectomy. The
researchers concluded that breast-conserving therapy is an
acceptable treatment option for patients with Paget's disease
of the breast that is confined to the nipple or areola region.
2
References:
1. Kawase K, DiMaio D, Tucker S, et al. Paget's disease of
the breast: a long-term follow-up study. Proceedings from
the 26th annual San Antonio Breast Cancer Symposium. December
2003. Abstract #449.
2. Joseph K, Komenaka I, Ditkoff B, et al. Therapeutic options
for Paget's disease: an update. Proceedings from the 26th
annual San Antonio Breast Cancer Symposium. December 2003.
Abstract #156.
© CancerConsultants.com
|